Literature DB >> 19953091

Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.

Ulrike Haug1, Sabrina Hundt, Hermann Brenner.   

Abstract

OBJECTIVES: Quantitative and qualitative immunochemical fecal occult blood tests (FOBTs) have been proposed for noninvasive colorectal cancer screening, but comparative evaluation is lacking. The aim of this study was to determine the diagnostic accuracy of two (quantitative) enzyme-linked immunosorbent assay (ELISA)-based immunochemical FOBTs for identifying colorectal adenomas in the target population of screening and to compare the results with six (qualitative) immunochromatographic FOBTs, previously evaluated in the same study participants using the same stool samples.
METHODS: A total of 1,319 participants of screening colonoscopy at average risk for colorectal neoplasia (mean age 63 years; age range 31-86 years; 50% men) were recruited prospectively from January 2006 to December 2007 in collaboration with 20 gastroenterological practices in Germany. Fecal hemoglobin and hemoglobin-haptoglobin levels were measured using an automated ELISA (RIDASCREEN). Test performance characteristics at different cutoff values were derived by comparing the results of stool testing with the results of colonoscopy in a blinded manner.
RESULTS: A total of 130 participants (10%) had an advanced adenoma. The area under the receiver-operating characteristic curve with regard to advanced adenomas was 0.68 (0.65-0.71) for hemoglobin and 0.64 (0.61-0.67) for hemoglobin-haptoglobin (P=0.034). At a specificity of approximately 95%, the sensitivity (95% confidence interval) for advanced adenomas was 33% (25-42%) for hemoglobin and 24% (17-32%) for hemoglobin-haptoglobin, respectively. The sensitivity for hemoglobin was very close to sensitivities of the six qualitative FOBTs at (strongly divergent) levels of specificity observed for the latter.
CONCLUSIONS: ELISA-based measurement of hemoglobin was superior to hemoglobin-haptoglobin, but showed a similar sensitivity for advanced adenomas compared with (qualitative) immunochromatographic FOBTs at defined levels of specificity. Compared with the latter, its quantitative nature offers advantages in terms of transparency and flexibility regarding the positivity threshold (e.g., specificity can be oriented toward available colonoscopy resources or personal risk profiles) and in terms of a higher level of standardization regarding test analysis and interpretation.

Entities:  

Mesh:

Year:  2009        PMID: 19953091     DOI: 10.1038/ajg.2009.668

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  35 in total

1.  Fecal immunochemical test accuracy in average-risk colorectal cancer screening.

Authors:  Vicent Hernandez; Joaquin Cubiella; M Carmen Gonzalez-Mao; Felipe Iglesias; Concepción Rivera; M Begoña Iglesias; Lucía Cid; Ines Castro; Luisa de Castro; Pablo Vega; Jose Antonio Hermo; Ramiro Macenlle; Alfonso Martínez-Turnes; David Martínez-Ares; Pamela Estevez; Estela Cid; M Carmen Vidal; Angeles López-Martínez; Elisabeth Hijona; Marta Herreros-Villanueva; Luis Bujanda; Jose Ignacio Rodriguez-Prada
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

2.  Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection.

Authors:  Ulrike Haug; Amy B Knudsen; Iris Lansdorp-Vogelaar; Karen M Kuntz
Journal:  Int J Cancer       Date:  2014-12-03       Impact factor: 7.396

3.  Sex is a stronger predictor of colorectal adenoma and advanced adenoma than fecal occult blood test.

Authors:  Monika Ferlitsch; Georg Heinze; Petra Salzl; Martha Britto-Arias; Elisabeth Waldmann; Karoline Reinhart; Christina Bannert; Elisabeth Fasching; Peter Knoflach; Werner Weiss; Michael Trauner; Arnulf Ferlitsch
Journal:  Med Oncol       Date:  2014-08-14       Impact factor: 3.064

4.  Diagnostic accuracy of fecal immunochemical test in average- and familial-risk colorectal cancer screening.

Authors:  Joaquín Cubiella; Inés Castro; Vicent Hernandez; Carmen González-Mao; Concepción Rivera; Felipe Iglesias; María Teresa Alves; Lucía Cid; Santiago Soto; Luisa De-Castro; Pablo Vega; Jose Antonio Hermo; Ramiro Macenlle; Alfonso Martínez; Pamela Estevez; Estela Cid; Marta Herreros-Villanueva; Isabel Portillo; Luis Bujanda; Javier Fernández-Seara
Journal:  United European Gastroenterol J       Date:  2014-12       Impact factor: 4.623

5.  The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer.

Authors:  Clarence K W Wong; Richard N Fedorak; Connie I Prosser; Marianne E Stewart; Sander Veldhuyzen van Zanten; Daniel C Sadowski
Journal:  Int J Colorectal Dis       Date:  2012-06-14       Impact factor: 2.571

6.  Evaluation of combined detection of multigene mutation and SDC2/SFRP2 methylation in stool specimens for colorectal cancer early diagnosis.

Authors:  Jie Lin; Lijing Zhang; Mengshi Chen; Juan Chen; Yijuan Wu; Tao Wang; Yan Lu; Zhaofen Ba; Xiaowei Cheng; Rongrong Xu; Tian Tian; Aijuan Sun; Tiantian Zhang; Minghong Chen
Journal:  Int J Colorectal Dis       Date:  2022-05-02       Impact factor: 2.571

Review 7.  Colorectal cancer screening--optimizing current strategies and new directions.

Authors:  Ernst J Kuipers; Thomas Rösch; Michael Bretthauer
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

Review 8.  Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Douglas J Robertson; Jeffrey K Lee; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-10-18       Impact factor: 10.864

9.  Use of a low cut-off value for the fecal immunochemical test enables better detection of proximal neoplasia.

Authors:  Jae Myung Cha; Joung Il Lee; Kwang Ro Joo; Hyun Phil Shin; Jung Won Jeun; Jun Uk Lim
Journal:  Dig Dis Sci       Date:  2013-08-04       Impact factor: 3.199

10.  Fecal immunochemical test for hemoglobin in combination with fecal transferrin in colorectal cancer screening.

Authors:  Anton Gies; Katarina Cuk; Petra Schrotz-King; Hermann Brenner
Journal:  United European Gastroenterol J       Date:  2018-06-12       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.